| Active substance | Talquetamab |
| Holder | Janssen-Cilag NV |
| Status | Running |
| Indication | As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 12/10/2023 |